Participant flow16

How many started, completed or left each group, period by period.

1 to 16 of 16

Period	Milestone	Group	Participants
Core Study	STARTED	Ruxolitinib	74
Core Study	STARTED	Best Available Therapy (BAT)	75
Core Study	Full Analysis Set	Ruxolitinib	74
Core Study	Full Analysis Set	Best Available Therapy (BAT)	75
Core Study	Crossover Set	Ruxolitinib	0
Core Study	Crossover Set	Best Available Therapy (BAT)	58
Core Study	COMPLETED	Ruxolitinib	59
Core Study	COMPLETED	Best Available Therapy (BAT)	61
Core Study	NOT COMPLETED	Ruxolitinib	15
Core Study	NOT COMPLETED	Best Available Therapy (BAT)	14
Crossover Period	STARTED	Ruxolitinib	0
Crossover Period	STARTED	Best Available Therapy (BAT)	58
Crossover Period	COMPLETED	Ruxolitinib	0
Crossover Period	COMPLETED	Best Available Therapy (BAT)	38
Crossover Period	NOT COMPLETED	Ruxolitinib	0
Crossover Period	NOT COMPLETED	Best Available Therapy (BAT)	20

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02038036/flow